Skip to main content

ATB Therapeutics has engineered a proprietary technology to manufacture a unique kind of immunotherapeutic designed to combine very high efficacy with unprecedent safety profile.
ATB Therapeutics was funded in 2017 and aims to generate a pipeline of assets for hard-to-treat hematological and solid cancers. The company is now entering preclinical stage.

Website